Triptans News and Research

RSS
NeurAxon’s NXN-188 compound effective for acute migraine treatment

NeurAxon’s NXN-188 compound effective for acute migraine treatment

MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

MAP Pharmaceuticals to present FREEDOM-301 Phase 3 trial data for migraine at EHMTIC Congress

Sales of Merck's telcagepant and CoLucid's lasmiditan in world's major markets to reach $1.3 billion in 2019

Sales of Merck's telcagepant and CoLucid's lasmiditan in world's major markets to reach $1.3 billion in 2019

High dose aspirin effective for treatment of severe headache and migraine

High dose aspirin effective for treatment of severe headache and migraine

Allergan receives UK MHRA authorisation of BOTOX for prophylaxis of headache in chronic migraine

Allergan receives UK MHRA authorisation of BOTOX for prophylaxis of headache in chronic migraine

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

MAP Pharmaceuticals to present new analyses on LEVADEX from FREEDOM-301 Phase 3 clinical trial

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

CoLucid's lasmiditan NAAMA effective in treatment of acute migraine attacks

Uninsured migraine sufferers likely to get inadequate treatment: Neurology

Uninsured migraine sufferers likely to get inadequate treatment: Neurology

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

Encouraging results from OptiNose's sumatriptan Phase II study for migraine

Survey: Acute migraine therapy would earn 45% patient share in treatment of migraine

Survey: Acute migraine therapy would earn 45% patient share in treatment of migraine

MAP Pharmaceuticals announces net loss of $13.4M for fourth-quarter 2009

MAP Pharmaceuticals announces net loss of $13.4M for fourth-quarter 2009

Aradigm's first U.S. sale of SUMAVEL DosePro needle-free delivery system triggers $4M milestone payment

Aradigm's first U.S. sale of SUMAVEL DosePro needle-free delivery system triggers $4M milestone payment

Sumavel DosePro and Levadex to earn up to $400M by 2018

Sumavel DosePro and Levadex to earn up to $400M by 2018

Phase 3 trial results of LEVADEX orally inhaled migraine therapy to be presented

Phase 3 trial results of LEVADEX orally inhaled migraine therapy to be presented

Investigational, orally-inhaled therapy effective in treating migraines

Investigational, orally-inhaled therapy effective in treating migraines

FDA approves Symbyax for treatment-resistant depression

FDA approves Symbyax for treatment-resistant depression

Savella - Fibromyalgia treatment approved by FDA

Savella - Fibromyalgia treatment approved by FDA

FDA approves tapentadol immediate-release tablets for pain in adults

FDA approves tapentadol immediate-release tablets for pain in adults

Medications containing barbiturates or narcotics may make migraine worse

Medications containing barbiturates or narcotics may make migraine worse

Trial demonstrates safety and efficacy of neurally acting anti-migraine agent for treatment of acute migraine

Trial demonstrates safety and efficacy of neurally acting anti-migraine agent for treatment of acute migraine